Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 0.0 | 0.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.96 | 2.26 |
NAV | ₹14.15 | ₹148.66 |
Fund Started | 07 Sep 2022 | 13 Oct 2005 |
Fund Size | ₹2573.87 Cr | ₹1385.43 Cr |
Exit Load | 0.5% for redemption within 90 Days | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 12.29% | 10.82% |
3 Year | - | 17.85% |
5 Year | - | 20.55% |
1 Year
3 Year
5 Year
Equity | 98.66% | 94.94% |
Cash | 1.34% | 3.99% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
ICICI Bank Ltd. | 4.96% |
Bharti Hexacom Ltd. | 3.64% |
Aster DM Healthcare Ltd. | 3.10% |
Axis Bank Ltd. | 3.08% |
Infosys Ltd. | 2.96% |
Brigade Enterprises Ltd. | 2.84% |
Vijaya Diagnostic Centre Ltd. | 2.82% |
HDFC Bank Ltd. | 2.77% |
Vishal Mega Mart Ltd. | 2.69% |
Century Plyboards (India) Ltd. | 2.67% |
Name | Assets |
---|---|
ICICI Bank Ltd. | 7.60% |
Axis Bank Ltd. | 6.91% |
Reliance Industries Ltd. | 5.65% |
Bharti Airtel Ltd. | 5.45% |
HDFC Bank Ltd. | 4.98% |
State Bank of India | 4.97% |
NTPC Ltd. | 4.55% |
Larsen & Toubro Ltd. | 4.01% |
Infosys Ltd. | 3.95% |
Sun Pharmaceutical Industries Ltd. | 3.17% |
Name | Pankaj Tibrewal | Sri Sharma |
Start Date | 07 Sep 2022 | 30 Apr 2021 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities with a focus on riding business cycles through dynamic allocation between various sectors and stocks at different stages of business cycles in the economy. | The scheme seeks to generate capital appreciation and income distribution to unit holders by investing predominantly in equity/equity related securities of the companies belonging to Exports & Services industry. |
Launch Date | 07 Sep 2022 | 13 Oct 2005 |
Description
Launch Date